Increased understanding of prostate cancer biology has led to new treatment strategies and promising new agents for treating prostate cancer, in particular peptide-based agonists and antagonists. In this review article, new therapy modalities and potential approaches for the treatment of advanced prostate cancer are discussed, including agonists and antagonists of luteinizing hormonereleasing hormone, antagonists of bombesin/gastrin-releasing peptide, and growth hormone-releasing hormone and somatostatin analogues. Though the prognosis of patients with prostate cancer is much improved by some of these treatment approaches, including combination treatment methods, extensive side-effects are still reported. These include sexual dysfunction, functional lesions of the liver and renal system, osteoporosis, anaemia and diarrhoea. Future studies should focus on new treatment agents and treatment approaches that can eliminate side-effects and improve quality of life in patients with prostate cancer on the basis of potent treatment efficacy.
Introduction
Prostate cancer, a urinary system disease, is a leading worldwide cause of death in the male population. In the USA, prostate cancer has surpassed lung cancer as the most common human cancer: 1 over 27 360 men died of prostate cancer in the USA in 2009. 2 An epidemiological study revealed that the incidence of prostate cancer in Asian populations is lower than that in European and US populations. 3 Due to the rapidly ageing Chinese population, however, the incidence of prostate cancer in China is rising considerably. 4 The pathogenesis of prostate cancer is not well understood. It is evident that there is a relationship between prostate cancer and sex hormone levels, especially androgen levels. 5 Men with higher androgen levels may have a higher incidence of prostate cancer. 5 Surgical castration and androgen deprivation therapies are potent treatments for androgen-dependent prostate cancer. 6 Although, radical prostatectomy for prostate Y Xu, YF Jiang, B Wu New agonist and antagonist treatments for prostate cancer cancer has been practiced for over a century, it is accepted that orchiectomy is associated with important psychological and sociological effects. 7 Androgen deprivation therapies can alleviate prostate cancer by limiting the production of testosterone which, in turn, limits the stimulation of cancer cell growth within the prostate. 6, 8 The overwhelming majority of men treated with androgen deprivation therapies develop disease progression to androgenindependent prostate cancer (AIPC) within 1.5 -4 years following treatment. 9 AIPC, also known as hormone-refractory prostate cancer (HRPC), is difficult to treat and the prognosis is extremely poor. For APIC, the median time to disease progression is 10 months. 10 Thus, it is crucial to find new ways to treat advanced prostate cancer to extend lifespan and improve quality of life.
Increased insight into the biology of prostate cancer and the emergence of new therapeutic strategies has changed approaches for treating patients with advanced disease. As well as androgen suppression therapy, radiotherapy is a commonly used mode of treatment for these patients, although it is accompanied by short-term and possible long-term sideeffects. 11 Short-term side-effects of radiotherapy for advanced prostate cancer include infertility or reduced fertility, discomfort, diarrhoea, cystitis, difficulty urinating and general side-effects such as tiredness and hair loss. Possible long-term side-effects of radiotherapy include impotence, infertility, bowel and bladder problems, and lymphoedema.
On the basis of recent advances in knowledge relating to the role of growth factors in the growth, neoplastic transformation and progression of prostate cancer, targeted therapies using agonists and antagonists, based on peptides, have been developed. These include agonists and antagonists of luteinizing hormonereleasing hormone (LHRH; also known as gonadotropin-releasing hormone or luliberin), antagonists of bombesin/gastrinreleasing peptide (GRP) and growth hormone-releasing hormone (GHRH) and somatostatin analogues. Some strategies are now widely used and some are in early development for treating patients with advanced prostate cancer. These strategies will be discussed in this review.
Review search strategy
An electronic search was conducted using the databases of MEDLINE, CANCERLIT, EMBASE and The Cochrane Library. No language or date restrictions were imposed. The search included the following key words using 'OR and 'AND' as described: (agonist OR antagonist OR analogue) AND (prostate cancer OR prostatic carcinoma). Other key words included treatment, therapy, hormone, radiation, chemotherapy, role, effect and side-effect. There were no other specific inclusion or exclusion criteria identified for the search. The reference lists of identified papers or reviews were also hand searched for further papers of interest. All three authors reviewed the identified materials and consensus on which papers to include in the review was reached after careful discussion.
Therapy with LHRH agonists BACKGROUND
Luteinizing hormone-releasing hormone -is a decapeptide hormone that is synthesized and released from neurons within the hypothalamus and is responsible for the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by the anterior pituitary gland. 12 In treating Y Xu, YF Jiang, B Wu New agonist and antagonist treatments for prostate cancer prostate cancer, LHRH agonists work through mimicking natural LHRH, which can downregulate LHRH receptors in the pituitary, leading to inhibition of FSH and LH release and a concomitant decrease in testosterone production. 13 -16 
SYNTHETIC LHRH AGONISTS
Synthetic agonistic analogues of LHRH have been used for the treatment of advanced prostate cancer since the early 1980s, when the potency of such agonists was discovered. 13 -15 The two most commonly used medications are leuprolide (Lupron ® [Abbott Laboratories, Abbott Park, IL, USA] or Eligard ® [Sanofi-Aventis, Bridgewater, NJ, USA]) and goserelin (Zoladex ® [AstraZeneca, Wilmington, DE, USA]). Leuprolide is usually administered via intramuscular injection into the gluteal region, whereas goserelin is usually administered subcutaneously into the abdomen. 17 Use of LHRH agonists to treat prostate cancer is associated with several side-effects including impotence, loss of libido, hot flushes, anaemia, weight gain, hair loss, osteopenia and, most commonly, symptoms relating to the urinary system. 14, 18 -20 Urinary tract side-effects include bladder pain, bloody or cloudy urine, burning sensation or pain whilst urinating, decrease in the frequency of urination or in the volume of urine, and frequency and difficulty in urinating. 18 Despite these sideeffects, the most common androgen deprivation therapy for prostate cancer involves use of LHRH agonists. 17
Therapy with LHRH antagonists BACKGROUND
Treatment with antagonists of LHRH leads to androgen deprivation, but direct effects on tumours may also play a role. Unlike LHRH agonists, LHRH antagonists block the LHRH receptor by pure antagonism and are not associated with an initial release of LH which induces an increase in testosterone levels after each LHRH agonist injection. LHRH antagonists have an immediate onset of action leading to fast and profound suppression of testosterone. 18, 21 They are, therefore, especially valuable in the treatment of patients with prostate cancer and a high prostate-specific antigen (PSA) serum level where fast control of disease is needed.
The LHRH receptors have been detected in the central nervous system and tissues of the breast, ovary, endometrium, placenta and gastrointestinal system, and in malignant tumours of the breast and ovary, 22 as well as in prostate cancer tissue, 23 suggesting that antagonists of LHRH may be more potent than agonists of LHRH at blocking LHRH.
LHRH ANTAGONISTS
Though several LHRH antagonists are available, degarelix (degarelix acetate; Firmagon ® ; Ferring Pharmaceuticals, Saint-Prex, Switzerland) is currently the only one approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of advanced prostate cancer. It is an injectable LHRH antagonist for patients with advanced prostate cancer, administered subcutaneously as two injections of 120 mg as a first dose followed by one injection of 80 mg monthly for all subsequent doses. By immediately binding to LHRH receptors in the pituitary gland, degarelix can block their interaction with LHRH producing a fast and profound reduction in levels of LH, FSH and, in turn, testosterone. 24 Many studies have shown that degarelix achieves fast, profound and sustained testosterone suppression, with an acceptable safety profile and fewer Y Xu, YF Jiang, B Wu New agonist and antagonist treatments for prostate cancer adverse effects compared with agonists and other antagonists of LHRH. 18,25 -28 Potential therapy with bombesin/GRP analogues or antagonists BACKGROUND Bombesin, a 14-amino acid peptide, was first isolated from the skin of the oriental firebellied toad Bombina orientalis. GRP -a functional homologue of bombesin -is a 27amino acid regulatory human peptide that stimulates gastrin release and regulates gastric acid secretion and enteric motor function. 29 Previous experiments have shown that bombesin plays a role in cancer, acting as an autocrine growth factor that stimulates tumour growth through specific receptors. 30, 31 Bombesin/GRP and their receptors appear to be involved in the proliferation of prostate cancer. 32, 33 Human prostate cancer (PC-3) cells have been shown to possess 44 000 bombesin receptor sites. 34 Considerable overexpression of GRP receptor has been found in human prostate tissues, 35 demonstrating that GRP receptors may be markers for early molecular events in prostate carcinogenesis and useful in differentiating prostate hyperplasia from prostate neoplasia. These findings provide a molecular basis for potential clinical applications such as GRP receptor scintigraphy for early tumour diagnosis, radiotherapy with radiolabelled bombesinlike peptide analogues and chemotherapy with cytotoxic bombesin analogues. 35 
BOMBESIN ANALOGUES
Several clinical trials and preclinical studies are in progress to investigate the use of bombesin peptide analogues in the diagnostic imaging targeting of GRP receptors in prostate cancer. 36, 37 In a phase I clinical study involving radioactivelylabelled 99m Tc-bombesin, a radioactive signal was found in the prostate tumour region within 4 min after intravenous administration of 0.7 µg 99m Tc-bombesin. 36 To date, several derivatives of bombesin and its truncated form have been prepared for imaging with single photon emission computed tomography or positron emission tomography, thereby providing potentially effective candidates for further clinical evaluation. 38 Cytotoxic analogues of bombesin are also being investigated because receptors for bombesin-like peptides are present on a wide variety of tumours, including prostate cancer tumours. 15 AN-215, a cytotoxic analogue of bombesin, has been shown to have a powerful inhibitory effect on the growth of PC-3 androgen-independent prostate cancers. 39 
BOMBESIN ANTAGONISTS
Increasing attention has been paid to developing hormone therapies based on bombesin antagonists following the discovery that bombesin/GRP function as autocrine growth factors and their receptors are involved in prostate cancer tumour progression. 32 15 These bombesin/GRP antagonists potently block the binding of bombesin to receptors and effectively suppress the growth of various cancer cell lines, including PC-82, PC-3, MDA-PCa-2b and DU-145 prostate cancer cell lines. 15,40 -42 The most powerful antagonists are the bombesin pseudononapeptides with modified C-and Nterminals of which RC-3940-II has shown a Y Xu, YF Jiang, B Wu New agonist and antagonist treatments for prostate cancer higher binding affinity to tumour cell receptors and greater antitumour activity than RC-3095. 43, 44 Studies into the possible application of bombesin/GRP antagonists for cancer are ongoing. A phase I trial of the bombesin/GRP antagonist RC-3095 in patients with advanced solid malignancies was completed in 2006. 45 Due to the occurrence of local toxicity at the injection site, however, the dose escalation procedure could not be fully evaluated up to a maximum tolerated dose; thus, a recommended dose of RC-3095 for phase II trials could not be clearly established. 45 Phase II trials for RC-3095, therefore, have not been registered or started. Considering the novelty of its mechanism of action and impressive preclinical antitumour activity, further studies exploiting new formulations or analogues of RC-3095 to decrease local toxicity are warranted.
Potential therapy with GHRH antagonists BACKGROUND
Growth hormone-releasing hormone -a hypothalamic peptide hormone -can stimulate the synthesis and release of GH by binding to specific GHRH receptors in the pituitary gland. 46 GHRH is present in many human cancers, such as pancreatic cancer, lung, breast, endometrial, ovarian and prostate cancer. 47 -51 Kiaris et al. 50 found that the level of GHRH in serum from nude mice bearing H-69 small cell lung cancer xenografts was higher than in tumour-free mice, demonstrating that GHRH is an endocrine growth factor for small cell lung cancer.
GHRH ANTAGONISTS
Antagonists of GHRH have been designed and synthesized to inhibit the secretion of GH from the pituitary by blocking the binding of hypothalamic GHRH to GHRH receptors. 14,15 GHRH antagonists can bind to GHRH receptors to inhibit the release of GH in vitro and in vivo. 15 In vitro study has revealed the presence of an intact prostatic GHRH autocrine pathway which may stimulate prostate cell proliferation and that this pathway might be disrupted by GHRH antagonists. 52 Various GHRH antagonists have been synthesized and been shown to have potency in inhibiting human experimental prostate cancers that are mediated by the tumour inducing GHRH receptors, however the mechanism is far from understood. It has been shown that GHRH antagonists can activate tumoral GHRH receptors and induce apoptosis in LNCaP human prostate cancer cells through a Ca 2+ -dependent pathway. 53 GHRH antagonists have also been found to inhibit the proliferation of human androgen-independent PC-3 and DU-145 prostate cancers by affecting protein kinase C, mitogen activated protein kinase and cjun intracellular signalling. 41 The antiproliferative effects of the GHRH antagonist MZ-J-7-138 on prostate cancers has been shown to involve p53 and p21 signalling. 54
Therapy with somatostatin analogues BACKROUND
Studies have confirmed the existence of neuroendocrine cells in prostate tissue, which can secrete multiple bioactive substances and play an important role in the growth and differentiation of prostate cancer. 55 A variety of somatostatin receptors are distributed in prostate cancer with neuroendocrine cell differentiation. 56, 57 In one study, 50% of human prostate carcinoma tissues were found to express somatostatin receptor 1 and somatostatin receptor 5, but did not express Y Xu, YF Jiang, B Wu New agonist and antagonist treatments for prostate cancer somatostatin receptors 2, 3 or 4. 56 Another study into the expression and distribution of somatostatin receptors in a number of prostate carcinoma tissues found that somatostatin receptors 1, 2, 3, and 4 were expressed in prostate carcinoma tissue with different levels of expression and distribution. 57 These investigations have shown that somatostatin and somatostatin analogues could potentially be used for targeted prostate cancer therapy.
SOMATOSTATIN ANALOGUES
Octreotide, an octapeptide ring compound, is a synthetic analogue of human somatostatin. 58 Octreotide has been approved by the FDA for the treatment of acromegaly, diarrhoea caused by Biorck-Thorson syndrome, erubescence and other symptoms caused by vasoactive intestinal peptide tumours, and it has also been approved by the EMEA for the treatment of acromegaly. Many studies have reported the outstanding antitumour effectiveness of octreotide in treating cancers including hepatoma, 59 gastric cancer 60 and breast cancer. 61 The detection of neuroendocrine differentiation and somatostatin receptors in prostatic carcinoma has led to new therapeutic ideas for treating prostate cancer using octreotide. Octreotide was found to relieve pain effectively and improve quality of life in hormone-refractory prostate cancer. 62 It has also been shown to upregulate the apoptosis profilin factor 1 in prostate cancer cells, supporting the theory that octreotide might have a therapeutic effect on prostate cancer. 63 Octreotide has also been shown to inhibit proliferation of a prostate cancer cell line by blocking the somatostatin receptor subtypes 1 -5 and by indirect antihormone action or direct inhibition of cell division. 64 In 2009, octreotide completed phase I and II clinical trials in the USA where it was found to have some therapeutic effect in the treatment of hormone-independent prostate cancer. 65 Octreotide has been approved to treat tumours that are positive for somatostatin receptor 2. Several reports have confirmed that octreotide may inhibit proliferation and promote apoptosis of the DU-145 and PC-3 prostate cancer cell lines, 63, 66, 67 which are known to express somatostatin receptor 2a, 65 suggesting that octreotide might be a potential treatment option for prostate cancer. Some previous clinical trials, however, have left uncertainties relating to the potential use of octreotide for treating prostate cancer, which mainly relate to the trial design 64 and the fact that not all prostate cancer patients are positive for somatostatin receptor 2.
Other somatostatin analogues, such as lanreotide and vapreotide (RC-160), have also been designed for use in treating prostate cancer. A phase I/II study of the somatostatin analogue, lanreotide, showed that 30 mg lanreotide given once a week intramuscularly to patients with metastatic hormone-refractory prostate cancer was well tolerated and gave a higher response rate and only minor toxicity compared with pretherapy; performance status and bone pain were improved in 40% and 35% of patients, respectively. 68 In total, 20% of the patients had a decrease of ≥ 50% in PSA levels and 16% showed a stabilization. 68 Lanreotide exerts its effects on prostate cancer through circulating levels of chromogranin-A, PSA and insulin-like growth factor-1 in advanced prostate cancer patients. 69 Lanreotide is currently in phase III trials for the treatment of nonmetastatic castration-resistant prostate cancer.
Therapy with the somatostatin analogue, vapreotide, provides much higher metabolic stability than its parent compound, however, 
Conclusions
Greater insight into the pathogenesis of prostate cancer and the emergence of new therapeutic strategies has changed approaches in treating patients with advanced prostate cancer. Increased attention has been paid to a number of peptide-based agonists and antagonists, and therapeutic effects have been much improved by their introduction. Combination therapy is now widely accepted for treating advanced prostate cancer. For example, treatment using radiotherapy together with LHRH agonists for androgen suppression has become a standard of care for locally advanced prostate cancer. 71 Targeted chemotherapy using peptide analogues, such as cytotoxic analogues of LHRH, somatostatin or bombesin, has potent effects on human experimental prostate cancers. 72 Most of the treatment approaches discussed in this review have improved the prognosis of patients with prostate cancer; however extensive side-effects remain an important issue. Future studies should focus on new treatment agents and approaches that can eliminate side-effects and further improve quality of life in patients with prostate cancer on the basis of potent treatment efficacy.
